NASDAQ:PTI - Proteostasis Therapeutics Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Proteostasis Therapeutics Inc Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $1.96 +0.03 (+1.55 %) (As of 01/17/2020 04:00 PM ET) Add Compare Today's Range$1.90Now: $1.96▼$2.0050-Day Range$1.23MA: $2.52▼$4.3452-Week Range$0.61Now: $1.96▼$4.72Volume1.97 million shsAverage Volume3.00 million shsMarket Capitalization$100.21 millionP/E RatioN/ADividend YieldN/ABeta0.29 ProfileAnalyst RatingsAdvanced ChartEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Proteostasis Therapeutics, Inc, a clinical stage biopharmaceutical company, discovers and develops novel therapeutics to treat cystic fibrosis (CF) and other diseases caused by an imbalance in the proteostasis network. The company's lead product candidates include cystic fibrosis transmembrane conductance regulator (CFTR) modulators comprising PTI-428, an amplifier, which has completed Phase II study; and PTI-801, a third generation corrector molecule and PTI-808, a potentiator molecule, which has completed Phase I study. Read More… Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:PTI Previous Symbol CUSIPN/A CIK1445283 Webhttp://www.proteostasis.com/ Phone617-225-0096Debt Debt-to-Equity Ratio0.18 Current Ratio6.89 Quick Ratio6.89Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$2.84 million Price / Sales35.29 Cash FlowN/A Price / Cash FlowN/A Book Value$2.25 per share Price / Book0.87Profitability EPS (Most Recent Fiscal Year)($1.61) Net Income$-61,830,000.00 Net MarginsN/A Return on Equity-69.86% Return on Assets-55.87%Miscellaneous Employees48 Outstanding Shares51,129,000Market Cap$100.21 million Next Earnings Date3/13/2020 (Estimated) OptionableOptionable Receive PTI News and Ratings via Email Sign-up to receive the latest news and ratings for PTI and its competitors with MarketBeat's FREE daily newsletter. NASDAQ:PTI Rates by TradingView Proteostasis Therapeutics (NASDAQ:PTI) Frequently Asked Questions What is Proteostasis Therapeutics' stock symbol? Proteostasis Therapeutics trades on the NASDAQ under the ticker symbol "PTI." How were Proteostasis Therapeutics' earnings last quarter? Proteostasis Therapeutics Inc (NASDAQ:PTI) released its quarterly earnings results on Thursday, November, 7th. The company reported ($0.25) EPS for the quarter, beating the Thomson Reuters' consensus estimate of ($0.40) by $0.15. View Proteostasis Therapeutics' Earnings History. When is Proteostasis Therapeutics' next earnings date? Proteostasis Therapeutics is scheduled to release their next quarterly earnings announcement on Friday, March 13th 2020. View Earnings Estimates for Proteostasis Therapeutics. What price target have analysts set for PTI? 3 brokerages have issued 1 year target prices for Proteostasis Therapeutics' stock. Their forecasts range from $4.00 to $14.00. On average, they anticipate Proteostasis Therapeutics' stock price to reach $8.67 in the next year. This suggests a possible upside of 342.2% from the stock's current price. View Analyst Price Targets for Proteostasis Therapeutics. What is the consensus analysts' recommendation for Proteostasis Therapeutics? 3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Proteostasis Therapeutics in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Proteostasis Therapeutics. What are Wall Street analysts saying about Proteostasis Therapeutics stock? Here are some recent quotes from research analysts about Proteostasis Therapeutics stock: 1. According to Zacks Investment Research, "Proteostasis Therapeutics, Inc. is a biopharmaceutical company which focuses on the discovery and development of novel therapeutics to treat diseases caused by an imbalance in the proteostasis network primarily in the United States. Proteostasis Therapeutics, Inc. is based in Cambridge, Massachusetts. " (11/13/2019) 2. Cantor Fitzgerald analysts commented, ": We reiterate our OW rating and are lowering out 12-month PT to $14 from $21 on Proteostasis (due to lowering the probability of success on the program from 55% to 40%). This morning, the company announced and hosted a conference call to provide results from the low- and high-dose data from the triplet (PTI-801/808/428) trial. Additionally, the company announced data from the combination studies of on top of SYMDEKO. We feel the results were inferior to our projections, but believe data by year-end 2019 could make the case whether PTI’s internal drugs could be a competitive entrant in cystic fibrosis (CF)." (3/25/2019) Has Proteostasis Therapeutics been receiving favorable news coverage? Media headlines about PTI stock have been trending somewhat negative on Friday, InfoTrie Sentiment reports. The research firm identifies positive and negative media coverage by reviewing more than six thousand blog and news sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Proteostasis Therapeutics earned a coverage optimism score of -1.2 on InfoTrie's scale. They also assigned media coverage about the company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an effect on the stock's share price in the near future. View News Stories for Proteostasis Therapeutics. Are investors shorting Proteostasis Therapeutics? Proteostasis Therapeutics saw a increase in short interest in December. As of December 31st, there was short interest totalling 5,190,000 shares, an increase of 56.8% from the December 15th total of 3,310,000 shares. Based on an average daily volume of 5,450,000 shares, the days-to-cover ratio is presently 1.0 days. Currently, 13.3% of the company's stock are sold short. View Proteostasis Therapeutics' Current Options Chain. Who are some of Proteostasis Therapeutics' key competitors? Some companies that are related to Proteostasis Therapeutics include Syros Pharmaceuticals (SYRS), Cue Biopharma (CUE), Mersana Therapeutics (MRSN), Mallinckrodt (MNK), Calithera Biosciences (CALA), Evolus (EOLS), Spectrum Pharmaceuticals (SPPI), Recro Pharma (REPH), Avid Bioservices (CDMO), Merus (MRUS), OptiNose (OPTN), Minerva Neurosciences (NERV), Stemline Therapeutics (STML), CytomX Therapeutics (CTMX) and Puma Biotechnology (PBYI). What other stocks do shareholders of Proteostasis Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Proteostasis Therapeutics investors own include BHP Group (BHP), Idera Pharmaceuticals (IDRA), Rite Aid (RAD), Clearside Biomedical (CLSD), Micron Technology (MU), Syndax Pharmaceuticals (SNDX), Amarin (AMRN), Corbus Pharmaceuticals (CRBP), Resonant (RESN) and Sorrento Therapeutics (SRNE). Who are Proteostasis Therapeutics' key executives? Proteostasis Therapeutics' management team includes the folowing people: Ms. Meenu Chhabra, Pres, CEO & Director (Age 47)Dr. Benito Munoz, Chief Scientific Officer (Age 57)Dr. Po-Shun Lee, Exec. VP & Chief Medical Officer (Age 50)Ms. Sandra Zimmerman, VP of Fin., Principal Financial Officer & Principal Accounting OfficerMs. Sheila Gilbride Wilson, Chief Operating Officer When did Proteostasis Therapeutics IPO? (PTI) raised $51 million in an IPO on Thursday, February 11th 2016. The company issued 3,900,000 shares at $12.00-$14.00 per share. Leerink Partners and RBC Capital Markets acted as the underwriters for the IPO and Baird and H.C. Wainwright & Co. were co-managers. How do I buy shares of Proteostasis Therapeutics? Shares of PTI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab. What is Proteostasis Therapeutics' stock price today? One share of PTI stock can currently be purchased for approximately $1.96. How big of a company is Proteostasis Therapeutics? Proteostasis Therapeutics has a market capitalization of $100.21 million and generates $2.84 million in revenue each year. The company earns $-61,830,000.00 in net income (profit) each year or ($1.61) on an earnings per share basis. Proteostasis Therapeutics employs 48 workers across the globe.View Additional Information About Proteostasis Therapeutics. What is Proteostasis Therapeutics' official website? The official website for Proteostasis Therapeutics is http://www.proteostasis.com/. How can I contact Proteostasis Therapeutics? Proteostasis Therapeutics' mailing address is 80 Guest Street Suite 500, Boston MA, 02135. The company can be reached via phone at 617-225-0096 or via email at [email protected] MarketBeat Community Rating for Proteostasis Therapeutics (NASDAQ PTI)Community Ranking: 2.2 out of 5 ( )Outperform Votes: 290 (Vote Outperform)Underperform Votes: 382 (Vote Underperform)Total Votes: 672MarketBeat's community ratings are surveys of what our community members think about Proteostasis Therapeutics and other stocks. Vote "Outperform" if you believe PTI will outperform the S&P 500 over the long term. Vote "Underperform" if you believe PTI will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 1/17/2020 by MarketBeat.com StaffFeatured Article: What are economic reports?
